Randy F Sweis

16PUBLICATIONS
124CO-AUTHORS
Medical infection agents (incl. prions)Cancer cell biologyPredictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|May 18, 2026
Lipid Nanoparticle-Encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ plus Durvalumab Induces an Immunostimulatory Effect within the Tumor Microenvironment in Patients with Advanced Solid Tumors.

|Oct 15, 2025
A Roadmap for the Future of Systems Biology in Cancer Research.

H Steven Wiley, Carlos F Lopez, Andrei S Rodin

|Jun 29, 2025
The current and future role of systemic therapy in non-muscle-invasive bladder cancer.

Alon Lazarovich, Randy F Sweis

|Jan 23, 2025
Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas.

Jason J Luke, Randy F Sweis, J Randolph Hecht

|Jan 14, 2025
PKCδ Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells.

Kyle R Cron, Ayelet Sivan, Keston Aquino-Michaels

|Nov 22, 2024
A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer.

Randy F Sweis, Gurkamal S Chatta, Rohit K Jain

Pageof 3

Frequent Collaborators

3 joint publications

Jason J Luke

2 joint publications

Nitya Nair

2 joint publications

Funda Meric-Bernstam

2 joint publications

Georgina V Long